A carregar...

Rituximab in Membranous Nephropathy: Not all studies are created equal

Many prospective studies and a recent randomized controlled trial have shown that the B-cell depleting monoclonal antibody rituximab safely promotes remission of nephrotic syndrome in approximately 65% of patients with membranous nephropathy (MN). Mechanistic studies have indicated that rituximab-in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nephron
Autor principal: Cravedi, Paolo
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5214174/
https://ncbi.nlm.nih.gov/pubmed/27676651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000450659
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!